The benefits of SGLT2 inhibitors include the prevention of microvascular and macrovascular complications arising from uncontrolled diabetes, a decrease in microalbuminuria, other nephroprotective effects, weight loss, and improved outcomes in heart failure [11,12]. This evidence concerns the gene SLC5A2 and diabetes mellitus.